Mesoblast LTD income statement

In fiscal 2026, Mesoblast LTD reported revenue of $120m, up 599.2% on the year before and net income of −$57.5m, or −$0.44 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Mesoblast LTD: income statement, annual
Fiscal year	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025	2026Jun 2026
Revenue	43	2	17	17	32	7	10	8	6	17	120
Cost of revenue	—	—	—	—	—	—	—	0	0	5	17
Gross profit	—	—	—	—	—	—	—	8	6	12	104
Research and development	50	59	66	60	56	53	33	53	40	35	98
Interest expense	—	—	2	12	15	16	17	19	21	22	20
Income before tax	−91	−90	−66	−99	−87	−100	−92	−82	−88	−102	−57
Income tax	−87	−13	−31	−9	−9	−1	−0	−0	−0	0	1
Net income	−4	−77	−35	−90	−78	−99	−91	−82	−88	−102	−58
Diluted EPS	−$0.11	−$1.93	−$0.76	−$1.82	−$1.47	−$1.63	−$1.34	−$1.05	−$0.89	−$0.85	−$0.44
Diluted shares (average)	36m	40m	47m	49m	53m	61m	68m	78m	99m	121m	129m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MESO vs RCUS MESO vs SPRY AGEN vs MESO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Mesoblast LTD's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Mesoblast LTD.